Skip to main
LXEO

LXEO Stock Forecast & Price Target

LXEO Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lexeo Therapeutics is a clinical-stage genetic medicine company with a pipeline of gene therapy candidates targeting cardiovascular diseases. The most advanced candidate, LX2006, is designed to deliver functional frataxin in patients with Friedreich's ataxia cardiomyopathy, while the next most advanced candidate, LX2020, is designed to deliver a functional PKP2 gene in arrhythmogenic cardiomyopathy patients. The company has a positive safety profile for systemic gene therapy and expects to engage with regulatory agencies in 2026 for its HEROIC program in PKP2-ACM. With forecasts for peak sales of $580.2 million in 2032 and $273.8 million in 2035 for LX2006 and LX2020, respectively, Lexeo's stock presents a promising investment opportunity.

Bears say

Lexeo Therapeutics is a clinical-stage genetic medicine company that is currently developing gene therapy treatments for cardiovascular diseases such as Friedreich's ataxia, cardiomyopathy, and arrhythmogenic cardiomyopathy. While the company's therapies have shown some promising efficacy signals, the data is still lacking in terms of showing a clear and consistent story. Furthermore, the company's programs face significant competition, and its current pipeline does not have a large market potential, leading to a negative outlook on its stock.

LXEO has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lexeo Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lexeo Therapeutics Inc (LXEO) Forecast

Analysts have given LXEO a Buy based on their latest research and market trends.

According to 8 analysts, LXEO has a Buy consensus rating as of Apr 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lexeo Therapeutics Inc (LXEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.